Increased RAHA Titer and Interleukin-6 Levels in the Synovial Fluid in a Patient with Polymyalgia Rheumatica.

Zen-Nyoji, Akiko; Shimizu, Hiroyuki; Ohtani, Ken-Ichi; Oshimoto, Kouichi; Kobayashi, Yoshinari; Mori, Masatomo

doi:10.2169/internalmedicine.32.484

Cited by 4 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the pathogenesis of this disorder remains unknown, IL-6 has been identified as the only cytokine occurring at a consistently high level in patients with the active form of the disease; it is recognized as the most sensitive indicator of disease activity and course. 107,109–111,135 IL-6 was also reported to be elevated in the synovial fluid 136 and in the muscle interstitial concentrations of cytokines. 137 IL-6 inhibition with TCZ may thus constitute a novel strategy for the treatment of PMR.…”

Section: Additional Applications Of Tocilizumab For Other Immune-medimentioning

confidence: 96%

Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases

Tanaka

Ogata

Narazaki

2013

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Interleukin-6 (IL-6), produced by a variety of cells, is a typical cytokine featuring redundancy and pleiotropic activity. IL-6 is promptly and transiently synthesized in response to infections or injuries, and participates in host defense by inducing immune responses, hematopoiesis, and acute-phase reactions. However, since its abnormal persistent production of mostly unknown etiology plays an important pathological role in the development of various immune-mediated diseases, a humanized anti-IL-6 receptor monoclonal antibody, tocilizumab, was developed and is now used as an innovative biologic for rheumatoid arthritis in more than 90 countries. Several factors strongly suggest that a IL-6 blockade strategy may have a broad application for the treatment of various immune-mediated diseases. These factors include favorable results of pilot or case studies with off-label use of tocilizumab, pathological analyses of the contribution of IL-6 to the development of immune-mediated diseases, and the potential capability of tocilizumab to both repair an imbalance of effector T cell subsets and to suppress pathologic autoantibody production. However, clinical trials to evaluate the efficacy and safety of tocilizumab for these diseases are essential. Furthermore, clarification of the cell source of IL-6 production and of the mechanisms through which dysregulated continuous IL-6 synthesis is induced constitutes an important issue for future studies into the pathogenesis of diseases.

show abstract

Section: Additional Applications Of Tocilizumab For Other Immune-medimentioning

confidence: 96%

Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases

Tanaka

Ogata

Narazaki

2013

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

show abstract

“…In patients with PMR, infiltration of macrophages and CD45RO + T cells and the expression of adhesion molecules, such as VCAM-1 and ICAM-1, have been observed in the synovia of the shoulders (2,3). It has also been reported that interleukin 6 levels are increased in the shoulder joints (4,5). One study found a decrease in CD4 + CD25 high Foxp3 + regulatory T cells and an increase in pro-inflammatory T cell subsets, such as Th1 and Th17, in the peripheral blood of PMR patients (6).…”

Section: Introductionmentioning

confidence: 97%

New-onset Polymyalgia Rheumatica Following the Administration of the Pfizer-BioNTech COVID-19 Vaccine

et al. 2022

View full text Add to dashboard Cite

We herein report the case of an 80-year-old Japanese woman who presented to our hospital with bilateral pain in the shoulders and hips lasting for a month since 2 days after the second dose of the BNT162b2 COVID-19 vaccine. Her physical findings, laboratory data, and ultrasonographic findings of bilateral biceps tenosynovitis and lateral subacromial bursitis were consistent with a diagnosis of polymyalgia rheumatica (PMR). She was successfully treated with oral prednisolone 15 mg/day. Although a causal relationship could not be definitively confirmed, PMR should be considered as a differential diagnosis in cases of persistent myalgia after administration of the BNT162b2 vaccine.

show abstract

The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle

Alegria

Boukhlal

Cornec

et al. 2020

Autoimmunity Reviews

View full text Add to dashboard Cite

Increased RAHA Titer and Interleukin-6 Levels in the Synovial Fluid in a Patient with Polymyalgia Rheumatica.

Cited by 4 publications

References 13 publications

Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases

Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases

New-onset Polymyalgia Rheumatica Following the Administration of the Pfizer-BioNTech COVID-19 Vaccine

The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle

Contact Info

Product

Resources

About